125 related articles for article (PubMed ID: 11124057)
1. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.
Reynolds PN; Zinn KR; Gavrilyuk VD; Balyasnikova IV; Rogers BE; Buchsbaum DJ; Wang MH; Miletich DJ; Grizzle WE; Douglas JT; Danilov SM; Curiel DT
Mol Ther; 2000 Dec; 2(6):562-78. PubMed ID: 11124057
[TBL] [Abstract][Full Text] [Related]
2. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo.
Reynolds PN; Nicklin SA; Kaliberova L; Boatman BG; Grizzle WE; Balyasnikova IV; Baker AH; Danilov SM; Curiel DT
Nat Biotechnol; 2001 Sep; 19(9):838-42. PubMed ID: 11533642
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to native mouse angiotensin-converting enzyme (CD143): ACE expression quantification, lung endothelial cell targeting and gene delivery.
Balyasnikova IV; Sun ZL; Metzger R; Taylor PR; Vicini E; Muciaccia B; Visintine DJ; Berestetskaya YV; McDonald TD; Danilov SM
Tissue Antigens; 2006 Jan; 67(1):10-29. PubMed ID: 16451197
[TBL] [Abstract][Full Text] [Related]
4. A novel system for mitigation of ectopic transgene expression induced by adenoviral vectors.
Reynolds PN; Holmes MD; Adachi Y; Kaliberova L; Curiel DT
Gene Ther; 2001 Aug; 8(16):1271-5. PubMed ID: 11509961
[TBL] [Abstract][Full Text] [Related]
5. Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats.
Miller WH; Brosnan MJ; Graham D; Nicol CG; Morecroft I; Channon KM; Danilov SM; Reynolds PN; Baker AH; Dominiczak AF
Mol Ther; 2005 Aug; 12(2):321-7. PubMed ID: 16043100
[TBL] [Abstract][Full Text] [Related]
6. Novel adenoviral gene delivery system targeted against head and neck cancer.
Li D; Guang W; Abuzeid WM; Roy S; Gao GP; Sauk JJ; O'Malley BW
Laryngoscope; 2008 Apr; 118(4):650-8. PubMed ID: 18176343
[TBL] [Abstract][Full Text] [Related]
7. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand.
Hoganson DK; Sosnowski BA; Pierce GF; Doukas J
Mol Ther; 2001 Jan; 3(1):105-12. PubMed ID: 11162317
[TBL] [Abstract][Full Text] [Related]
8. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector.
Reynolds P; Dmitriev I; Curiel D
Gene Ther; 1999 Jul; 6(7):1336-9. PubMed ID: 10455445
[TBL] [Abstract][Full Text] [Related]
9. Localized adenovirus gene delivery using antiviral IgG complexation.
Levy RJ; Song C; Tallapragada S; DeFelice S; Hinson JT; Vyavahare N; Connolly J; Ryan K; Li Q
Gene Ther; 2001 May; 8(9):659-67. PubMed ID: 11406760
[TBL] [Abstract][Full Text] [Related]
10. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
11. Long-term retinal transgene expression with FIV versus adenoviral vectors.
Loewen N; Leske DA; Cameron JD; Chen Y; Whitwam T; Simari RD; Teo WL; Fautsch MP; Poeschla EM; Holmes JM
Mol Vis; 2004 Apr; 10():272-80. PubMed ID: 15094709
[TBL] [Abstract][Full Text] [Related]
12. Advances towards targetable adenovirus vectors for gene therapy.
Einfeld DA; Roelvink PW
Curr Opin Mol Ther; 2002 Oct; 4(5):444-51. PubMed ID: 12435045
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
14. Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector.
Kreppel F; Luther TT; Semkova I; Schraermeyer U; Kochanek S
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1965-70. PubMed ID: 12037006
[TBL] [Abstract][Full Text] [Related]
15. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents.
Howard CM; Forsberg F; Minimo C; Liu JB; Merton DA; Claudio PP
J Cell Physiol; 2006 Nov; 209(2):413-21. PubMed ID: 16883597
[TBL] [Abstract][Full Text] [Related]
17. Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors.
Everett RS; Evans HK; Hodges BL; Ding EY; Serra DM; Amalfitano A
Virology; 2004 Jul; 325(1):96-105. PubMed ID: 15231389
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control.
Work LM; Ritchie N; Nicklin SA; Reynolds PN; Baker AH
Gene Ther; 2004 Aug; 11(16):1296-300. PubMed ID: 15292916
[TBL] [Abstract][Full Text] [Related]
20. Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors.
Everts M; Kim-Park SA; Preuss MA; Passineau MJ; Glasgow JN; Pereboev AV; Mahasreshti PJ; Grizzle WE; Reynolds PN; Curiel DT
Gene Ther; 2005 Jul; 12(13):1042-8. PubMed ID: 15789059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
